IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v19y2022i19p12130-d924796.html
   My bibliography  Save this article

Understanding the Actual Use of Anti-HIV Drugs in Japan from 2016 to 2019: Demonstrating Epidemiological Relevance of NDB Open Data Japan for Understanding Japanese Medical Care

Author

Listed:
  • Hiroyuki Tanaka

    (Department of Practical Pharmacy, Faculty of Pharmaceutical Sciences, Toho University, 2-2-1 Miyama, Funabashi, Chiba 274-8510, Japan)

  • Toshihisa Onoda

    (Department of Practical Pharmacy, Faculty of Pharmaceutical Sciences, Toho University, 2-2-1 Miyama, Funabashi, Chiba 274-8510, Japan)

  • Toshihiro Ishii

    (Department of Practical Pharmacy, Faculty of Pharmaceutical Sciences, Toho University, 2-2-1 Miyama, Funabashi, Chiba 274-8510, Japan)

Abstract

The National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB) Open Data Japan is helpful for attaining simple and comprehensive understanding of medical care in Japan. Herein, we investigated the transition of anti-HIV-drug use in Japan over a 4-year period from fiscal year (FY) 2016 to FY 2019 using data on anti-HIV drugs that were extracted from the 3rd, 4th, 5th, and 6th NDB Open Data Japan. Then, the data were stratified by mechanism of action, single-tablet regimen (STR) or non-STR, age groups, and sex and analyzed. Throughout the study period, the prescription volume for tenofovir alafenamide fumarate as the backbone drug and integrase strand transfer inhibitors as the anchor drug increased. In FY 2019, STRs constituted approximately 44% of the total combination antiretroviral therapy regimens, 1.6 times higher than that in FY 2016 (27%). With the advent of newer drugs and regimens, the differences in anti-HIV drugs prescribed to patients of different ages and sex gradually diminished; however, differences were unremarkable in the first period, especially between sexes. The NDB Open Data Japan made it relatively easy to evaluate recent trends in anti-HIV prescription in Japan, indicating its usefulness for continuous surveys in this field.

Suggested Citation

  • Hiroyuki Tanaka & Toshihisa Onoda & Toshihiro Ishii, 2022. "Understanding the Actual Use of Anti-HIV Drugs in Japan from 2016 to 2019: Demonstrating Epidemiological Relevance of NDB Open Data Japan for Understanding Japanese Medical Care," IJERPH, MDPI, vol. 19(19), pages 1-11, September.
    • Handle: RePEc:gam:jijerp:v:19:y:2022:i:19:p:12130-:d:924796
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/19/19/12130/pdf
    Download Restriction: no
    File URL: https://www.mdpi.com/1660-4601/19/19/12130/
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Laurent Cotte & Tristan Ferry & Pascal Pugliese & Marc-Antoine Valantin & Clotilde Allavena & André Cabié & Isabelle Poizot-Martin & David Rey & Claudine Duvivier & Antoine Cheret & Pierre Dellamonica, 2017. "Effectiveness and tolerance of single tablet versus once daily multiple tablet regimens as first-line antiretroviral therapy - Results from a large french multicenter cohort study," PLOS ONE, Public Library of Science, vol. 12(2), pages 1-12, February.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Sophie Degroote & Linos Vandekerckhove & Dirk Vogelaers & Charlotte Vanden Bulcke, 2022. "Patient-reported outcomes among people living with HIV on single- versus multi-tablet regimens: Data from a real-life setting," PLOS ONE, Public Library of Science, vol. 17(1), pages 1-15, January.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:19:y:2022:i:19:p:12130-:d:924796. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.